文献速递免疫规划

大肠杆菌表达的重组截短gD糖蛋白作为耐热且具保护性的传染性喉气管炎病毒亚单位疫苗候选

Recombinant truncated gD glycoprotein from E.coli as a thermostable and protective subunit vaccine candidate against ILTV in chickens.
PubMed 文献 · Vaccine · 2025-10-22

研究设计四种基于生物信息学分析的ILTV糖蛋白gB和gD截短片段,其中gBb和gD在大肠杆菌中表达、gD在杆状病毒系统中表达,三种重组蛋白经NanoDSF和ELISPOT证实具有良好热稳定性和强免疫原性;SPF鸡免疫后以强毒株HB201806攻击,E.coli-gD诱导最强的体液和细胞免疫应答,所有免疫组临床症状减轻、死亡率降低,气管和哈德氏腺病毒载量不同程度下降,E.coli-gD组保护效力最佳。

要点

  • 大肠杆菌表达的截短gD蛋白经NanoDSF和ELISPOT证实热稳定性好、免疫原性强。
  • E.coli-gD免疫组在ELISA和流式细胞术检测中诱导最强的体液和细胞免疫应答。
  • 所有免疫组较攻击对照组临床症状减轻、死亡率降低,E.coli-gD组保护效力最佳。

核心结论

  • 重组gD尤其大肠杆菌表达形式是热稳定、高免疫原性且具保护性的ILTV亚单位疫苗候选。

研究设计与样本

  • 基于生物信息学分析设计ILTV糖蛋白gB和gD的四种截短片段gBa、gBb、gB和gD。
  • gBb和gD在大肠杆菌中表达,gD同时在杆状病毒系统中表达。
  • SPF鸡以弗氏佐剂配方的E.coli-gBb、E.coli-gD、E.coli-gBb+gD或Bac-gD蛋白免疫,随后以强毒ILTV株HB201806攻击。

主要发现

  • NanoDSF和ELISPOT证实E.coli-gBb、E.coli-gD和Bac-gD三种重组蛋白具有良好热稳定性和强免疫原性。
  • ELISA和流式细胞术显示E.coli-gD诱导最强的体液和细胞免疫应答。
  • 与攻击对照组相比,所有免疫组临床症状减轻、死亡率降低。
  • 感染高峰期气管和哈德氏腺病毒载量不同程度下降,E.coli-gD组保护效力最佳。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infectious laryngotracheitis virus (ILTV) is a major respiratory pathogen in poultry, and current vaccines pose safety risks or offer limited protection. To develop safer alternatives, we designed four truncated fragments of ILTV glycoproteins gB and gD (designated gBa, gBb, gB, and gD) based on bioinformatic analysis. The gBb and gD were successfully expressed in Escherichia coli (E.coli), and gD also in a baculovirus system. Three recombinant proteins (E.coli-gBb, E.coli-gD, and Bac-gD) showed favorable thermal stability and strong immunogenicity, as confirmed by NanoDSF and ELISPOT assays. SPF chickens were immunized with Freund's adjuvant-formulated E.coli-gBb, E.coli-gD, E.coli-gBb + gD, or Bac-gD proteins, followed by challenge with the virulent ILTV strain HB201806. Post-vaccination evaluation by ELISA and flow cytometry revealed that E.coli-gD induced the most robust humoral and cellular immune responses. Compared to the challenged control group, all immunized groups exhibited attenuated clinical symptoms and reduced mortality. Furthermore, at the peak of infection, viral loads in the trachea and Harderian glands were reduced to varying extents, with the E.coli-gD group demonstrating the greatest protective efficacy. These results indicate that recombinant gD, particularly the E.coli-expressed form, is a thermally stable, highly immunogenic, and protective subunit vaccine candidate for ILTV control in poultry.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhang X, Li Y, Tian J, et al. Recombinant truncated gD glycoprotein from E.coli as a thermostable and protective subunit vaccine candidate against ILTV in chickens. Vaccine. 2025. PMID: 41129887. doi:10.1016/j.vaccine.2025.127882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。